Clinical trials: Depressive Syndrome
Premenstrual Dysphoric Disorder
A Study of Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)
The objective of this phase IIb study is to evaluate the effect and safety of Sepranolone (UC1010) on premenstrual symptoms in women with Premenstrual Dysphoric Disorder (PMDD).
- Trial name
- NCT03697265
- Testing
- Sepranolone (UC1010) low dose, Sepranolone (UC1010) high dose
- Where
- 12 sites in Germany, Poland and 2 more
- Volunteers
- 475 people
- Sponsor
- Asarina Pharma
Post-Concussion Symptoms, Insomnia
Neurotechnology Following Traumatic Brain Injury
This two-part study seeks to improve symptoms such as pain and sleep problems after concussion, or mild traumatic brain injury (mTBI).
- Conditions
- Post-Concussion Symptoms, Insomnia, Pain, Chronic, Depressive Symptoms
- Trial name
- Cereset (NCT03649958)
- Testing
- HIRREM-SOP or Cereset, Cereset 2x
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Brain State Technologies, LLC
Premenstrual Dysphoric Disorder
Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
The objective of this study is to evaluate the effectiveness and safety in double-blind, randomized, placebo-controlled clinical trials of self administered PH80 intranasal spray for the acute management of cycle related symptoms…
- Trial name
- PH80-PMD (NCT01217775)
- Testing
- PH80
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Pherin Pharmaceuticals, Inc.
Premenstrual Dysphoric Disorder ( PMDD), PMDD
MLS101 Study in PMDD
The goal of this clinical trial is to learn if MLS101 (psilocybin) is a possible treatment for women with Premenstrual Dysphoric Disorder (PMDD).
- Trial name
- NCT07818720
- Testing
- MLS101 psilocybin
- Volunteers
- 32 people
- Sponsor
- MycoMedica Life Sciences PBC
Depressive Symptoms
EVALUATION OF EFFICACY OF SAMEUP IN SUBJECTS WITH DEPRESSION SYMPTOMS: A RANDOMIZED STUDY
This study is planned to assess the efficacy of SAMEUp versus placebo after six weeks of treatment in subjects characterized by depression symptoms according to ICD-10 (International Classification of Diseases - 10th revision)…
- Trial name
- SAMEUP (NCT03932474)
- Testing
- SAMEUp
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Nutrilinea srl
Depression, Depressive Disorder
A Treatment for Depression Via a Gamified Mobile Phone Application Based on a New Cognitive Model
The study is a randomized controlled treatment study comparing changes in depressive symptoms over 8 weeks between individuals with Major Depressive Disorder (MDD) who have access to an FTP-based mobile phone application and a…
- Conditions
- Depression, Depressive Disorder, Clinical Depression, Major Depressive Disorder
- Trial name
- FTP (NCT05685758)
- Testing
- FTP-based therapeutic mobile-app
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Hedonia Ltd
Contraception, Premenstrual Syndrome
Regulatory Post Marketing Surveillance Study on YAZ
The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice.
- Conditions
- Contraception, Premenstrual Syndrome, Acne
- Trial name
- NCT00998257
- Testing
- EE20/DRSP (YAZ, BAY86-5300)
- Where
- South Korea
- Volunteers
- 770 people
- Sponsor
- Bayer
Premenstrual Syndrome, Premenstrual Dysphoric Disorder
CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life
This study evaluates the feasibility and efficacy of the Samphire Guided Care (SGC) program a 12-week structured digital health program combining clinician-led onboarding, at-home neuromodulation using the Lutea tDCS device…
- Conditions
- Premenstrual Syndrome, Premenstrual Dysphoric Disorder, Dysmenorrhea, Endometriosis
- Trial name
- CREST (NCT07679074)
- Testing
- Lutea Transcranial Direct Current Stimulation (tDCS) Device, Samphire Guided Care Program
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Samphire Group, Inc.
Premenstrual Dysphoric Disorder
A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD)
The study is a phase 1/2 study in two parts. In part 1, the primary objective is to assess the pharmacokinetics of UC1010 when administered subcutaneously as a single dose to healthy women.
- Trial name
- NCT01875718
- Testing
- UC1010
- Where
- Sweden
- Volunteers
- 146 people
- Sponsor
- Umecrine Mood AB
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Premenstrual Dysphoric Disorder ( PMDD)
YAZ Premenstrual Dysphoric Disorder (PMDD) in China
The purpose of this study is to evaluate the efficacy and safety of YAZ compared to placebo in the treatment of symptoms related to Premenstrual Dysphoric Disorder (PMDD).
- Trial name
- NCT00824187
- Testing
- EE20/DRSP(YAZ, BAY86-5300)
- Where
- 16 sites in China
- Volunteers
- 187 people
- Sponsor
- Bayer
Depressive Disorder
Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients
This is an open label, randomized, add-on, 8 weeks multicentre study to evaluate the efficacy and safety of paroxetine Controlled Release (CR) in patients with Major Depressive Disorder (MDD) comorbid Irritable Bowel Syndrome…
- Trial name
- NCT01916200
- Testing
- Paroxetine CR
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Depression
GW679769 In Fibromyalgia
The purpose of the study is to investigate safety, tolerability and efficacy of oral GW679769 up to 120 mg dose compared to placebo in patients with ACR(American College of Rheumatology)-defined fibromyalgia, co-morbid with…
- Conditions
- Depressive Disorder, Depression, Fibromyalgia
- Trial name
- NCT00264628
- Testing
- GW679769
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Sleep Disorders, Obstructive Sleep Apnea
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
The primary objective of the study is to evaluate whether armodafinil at a target dosage of 200 mg/day is more effective than placebo treatment in improving excessive sleepiness in patients with obstructive sleep apnea/hypopnea…
- Conditions
- Sleep Disorders, Obstructive Sleep Apnea, Major Depressive Disorder, Dysthymic Disorder
- Trial name
- NCT00518986
- Testing
- armodafinil
- Where
- 62 sites in United States
- Volunteers
- 249 people
- Sponsor
- Cephalon
Depression, Post-Traumatic Stress Disorder
Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention
Background: Current military involvement in Afghanistan (Operation Enduring Freedom - OEF) and Iraq (Operation Iraqi Freedom - OIF) has created unforeseen burdens on the mental health and well-being of US service women and men.
- Conditions
- Depression, Post-Traumatic Stress Disorder, Functional Status
- Trial name
- NCT01231711
- Testing
- Vets Prevail
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Prevail Health Solutions, LLC
Depressive Syndrome, Anxiety
Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients
In this study we will assess as a primary objective the effect of venlafaxine retard treatment on primary care attended elderly patients with depressive syndrome.
- Trial name
- NCT00247429
- Volunteers
- 59 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer